Seres Therapeutics reported strong advancements in its SER-155 biotherapeutic program, particularly ahead of its Phase II study aimed at preventing bloodstream infections in vulnerable patients, buoyed by favorable FDA feedback and a strategic cost reduction initiative.

• SER-155's Phase Ib study demonstrated a 77% relative risk reduction in bacterial bloodstream infections, positioning it as a potential breakthrough therapy for allo-HSCT patients.
• The FDA provided constructive feedback that aligns with the Phase II study's design, including the approved dosing regimen and interim analysis plan.
• Secured a $3.6 million non-dilutive grant from CARB-X to support the development of a new oral liquid formulation of SER-155 for higher accessibility among medically vulnerable patients.
• 25% workforce reduction implemented to extend cash runway and focus on core development priorities, enhancing operational efficiency amidst capital-seeking efforts.